United Therapeutics Corp

UTHRNASDAQ • USD
ThemeBiotech - Drug Development›Rare Disease Therapeutics
568.43 USD
↗ 2.56 (0.45%)AT CLOSE (11:59 AM EDT)
568.09
↘ 0.34 (0.06%)
POST MARKET (AS OF 05:37 PM EDT)
Post Market
AS OF 05:37 PM EDT
568.09
↘ 0.34 (0.06%)
🔴Market: CLOSED
Open?$567.30
High?$570.64
Low?$563.04
Prev. Close?$565.87
Volume?281.0K
Avg. Volume?423.0K
VWAP?$567.78
Rel. Volume?0.66x
Bid / Ask
Bid?$522.55 × 40
Ask?$580.00 × 200
Spread?$57.45
Midpoint?$551.28
Valuation & Ratios
Market Cap?24.1B
Shares Out?42.4M
Float?41.7M
Float %?96.8%
P/E Ratio?18.74
P/B Ratio?4.09
EPS?$30.33
Dividend?0.00%
Ex-Dividend?N/A

Shares of United Therapeutics Corp (UTHR) are trading at $568.43. The technical outlook is "Neutral" and the fundamental picture shows "Neutral". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 2/9, exceptional Return on Equity (21.8%) and a bullish Golden Cross on the moving averages. On valuation, UTHR trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of May 22, 2026.

News
Profile
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
Themes
Biotech - Drug Development›Rare Disease Therapeutics
Employees
1.4K
Market Cap
24.1B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.unither.com
Listed
1999-06-17
Address
1000 SPRING ST
SILVER SPRING, MD 20910
Phone: (301) 608-9292
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
100
Momentum?
23
Short Sent.?
68
Piotroski F-Score?2/9Weak
Altman Z-Score?21.23Safe
Confidence?58%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?5.88%Elevated
Short Interest?2.4M
Days to Cover?6.5
Free Float41.7M
Avg Daily Volume377.5K
Settlement Date2026-04-30
Financial Health
Current Ratio?4.79Strong
Quick Ratio?4.50Strong
Cash Ratio?2.14Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
56/100
P/E?
Peers
100
S&P
69
18.7FAIR▾
P/B?
Peers
100
S&P
44
4.09FAIR▾
P/S?
Peers
100
S&P
15
7.61HIGH▾
P/FCF?
Peers
100
S&P
43
23.7FAIR▾
EV/EBITDA?
Peers
100
S&P
50
15.0FAIR▾
EV/Sales?
Peers
100
S&P
19
7.21HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
70
21.8%STRONG▾
ROA?
Peers
50
S&P
94
19.2%STRONG▾
Cash Flow & Enterprise
FCF?$1.0B
Enterprise Value?$22.8B
Fundamentals ratios updated end of day
MarketsMoversWatchlist